Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder

NCT00722254 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

NCT NCT00722254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00722254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder
Lead sponsor
University of Utah
Phase
Observational
Overall status
Terminated
Start date
June 30, 2006
Completion date
February 28, 2009
Enrollment
15 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

primary myelofibrosis, primary pulmonary hypertension, pulmonary arterial hypertension, secondary myelofibrosis